Piracetam
Piracetam
The original nootropic compound that enhances memory, learning, and cognitive function by modulating neurotransmitter systems.
Piracetam was the first compound classified as a 'nootropic' by Dr. Corneliu Giurgea in 1972. It enhances cognitive function through multiple mechanisms including improved membrane fluidity, modulation of AMPA receptors, and enhanced cholinergic neurotransmission. It's particularly noted for benefits in elderly cognitive decline and has been studied for decades with a strong safety profile. Best effects are often seen when combined with a choline source.
Mechanisms of Action
AMPA Receptor Modulation
Positive allosteric modulator of AMPA receptors
Membrane Fluidity
Improves neuronal membrane flexibility
Cholinergic Enhancement
Increases acetylcholine activity
Recommended Dose
1200-4800mg daily in divided doses
Loading: Some use 2-3x normal dose for first few days; not required
Optimal Timing
- Divided into 2-3 doses
- Morning and early afternoon
- With a choline source
Can be taken without food
Best Form
Piracetam powder or capsules
Available as powder (economical) or capsules. Bulk powder requires accurate dosing scale.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: 8-12 weeks on, 2-4 weeks off; or continuous use is reported safe by many
Note: Water-soluble and well-absorbed. Combining with Alpha-GPC or CDP-Choline prevents headaches and enhances effects.
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Memory Enhancement
Improved verbal memory and learning
Cognitive Clarity
Clearer thinking and mental processing
Neuroprotection
Protection against cognitive decline
Headache (if low choline)
Can cause headaches without adequate choline
Well-studied population; may see greatest benefits
Who Should NOT Take This
- Severe kidney impairment (excreted renally)
- Huntington's disease (theoretical concern)
Drug Interactions
May slightly enhance anticoagulant effects
Possible Side Effects
Tip: Take with choline source (Alpha-GPC, CDP-Choline)
Tip: Avoid evening doses
Warnings
- Not FDA-approved in US (sold as supplement/research compound)
- Combine with choline to prevent headaches
- Regulatory status varies by country
Alpha-GPC
essentialProvides choline for enhanced effects
Stronger cognitive benefits, prevents headaches
Aniracetam
complementaryDifferent receptor profiles complement each other
Broader cognitive enhancement
Choline
complementaryRacetams may increase acetylcholine demand
Prevents headaches from racetam use; enhanced cognitive effects
Noopept
complementaryDifferent mechanisms complement each other
Synergistic cognitive enhancement
Oxiracetam
complementaryDifferent receptor profiles
Broader nootropic effects
Top studies from 40+ peer-reviewed papers
Ricci S et al. • The Cochrane database of systematic reviews (2012)
“There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials.”
Key Findings:
- We included three trials involving 1002 patients, with one trial contributing 93% of the data.
- Piracetam was associated with a statistically non-significant increase in death at one month (approximately 31% increase, 95% confidence interval 81% increase to 5% reduction).
- There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials.
- There is not enough evidence to assess the effect of piracetam on dependence.
Liang CW et al. • Progress in neuro-psychopharmacology & biological psychiatry (2025)
“Published by Elsevier Inc.”
Key Findings:
- Notably, memantine, N-acetylcysteine, and sarcosine exhibited efficacy across multiple outcome domains.
- The effects of some novel agents within specific dose ranges on cognitive function improvement were also observed.Copyright © 2024.
- Published by Elsevier Inc.
Verdijk JPAJ et al. • Acta psychiatrica Scandinavica (2022)
“Memantine and liothyronine are promising for further research and future application.”
Key Findings:
- Low-quality evidence of efficacy was established for memantine (large effect size) and liothyronine (medium effect size).
- Memantine and liothyronine are promising for further research and future application.
- Quality of evidence was low because of differences in ECT techniques, study populations and cognitive measurements.
- These findings provide a guide for rational choices of potential pharmacological intervention research targets to decrease the burden of cognitive side effects of ECT.
Perng CH et al. • Psychopharmacology (2018)
“The most effective intervention for dementia available is symptomatic treatment for vascular dementia.”
Key Findings:
- The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
- The most effective intervention for dementia available is symptomatic treatment for vascular dementia.
- Antipsychotic treatment for dementia alleviates cognitive dysfunction less effectively than does symptomatic treatment.
- Alternative therapies are also effective at present.
Nistor M et al. • International journal of molecular sciences (2017)
“This important topic therefore requires more in-depth research.”
Key Findings:
- We identified three subsets of results: (1) hypothermia; (2) fluid therapy and/or vasopressors; and (3) other neuroprotective strategies (piracetam, NHE1-inhibition, aprotinin, human mesenchymal stem cells, remote ischemic preconditioning and sevoflurane).
- Overall, risk of bias according to SYRCLE's tool was medium; generally, animal experimental models require more rigorous adherence to the reporting of bias-free study design (randomization, etc.).
- While the individual study results are promising, the retrieved neuroprotective strategies have to be evaluated within the current scientific context-by doing so, it becomes clear that specific promising neuroprotective strategies during states of haemorrhagic shock remain sparse.
- This important topic therefore requires more in-depth research.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.